New generation combination product companies left high and dry by FDA
This article was originally published in Clinica
The FDA needs to draft guidance in the next year or two on what procedures companies should follow if they want to modify combination products, the Regulatory Affairs Professionals Society (RAPS) decided during a two-day consensus summit in Baltimore, Maryland, last week.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.